Suchergebnisse

Multivariate Analysis in the Pharmaceutical Industry provides industry practitioners with guidance on multivariate data methods and their applications over the lifecycle of a pharmaceutical product, from process development, to routine manufacturing, focusing on the challenges specific to each step. It includes an overview of regulatory guidance specific to the use of these methods, along with perspectives on the applications of these methods that allow for testing, monitoring and controlling products and processes. The book seeks to put multivariate analysis into a pharmaceutical context for the benefit of pharmaceutical practitioners, potential practitioners, managers and regulators. Users will find a resources that addresses an unmet need on how pharmaceutical industry professionals can extract value from data that is routinely collected on products and processes, especially as these techniques become more widely used, and ultimately, expected by regulators

The pharmaceutical industry has been enormously profitable for many decades. The myth is that these windfalls are warranted by the therapeutic advances made by pharmaceutical companies—but the reality is far different.Click here to purchase a PDF version of this article at the Monthly Review website.

How are pharmaceutical technologies developed and controlled in our societies? To what extent should the availability of these technologies be determined by scientific experts, a democratic state, the interests of final users, or ethical principles? This unique collection brings together the work of social scientists, ethicists, lawyers and policy analysts on regulation, ethics and innovation in the pharmaceutical industry. Regulatory systems and their implications for public health in North America, Europe and developing countries are discussed, including case studies of norplant, interferon and anti-fertility vaccines.

This study statistically examines the key determinants of compensation for CEOs in the pharmaceutical industry. Size, as measured by the log of the company's market value, provides the greatest explanatory power, in addition to the value of the CEO's holdings in the company and the composition of those holdings. The absolute number of employees provides a better explanation for smaller companies in the industry. An interesting relationship appears between the CEO's wealth and the total return of the company, perhaps suggesting that stock options provide some incentive for the CEO to maximize his total wealth by improving the company's market value and the stockholders' total return.